Payment overview · 2025
General Payments
$821.26
35 reported records · 10 companies
Healthcare provider profile · identity verified
David Smith, DNP, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SAN AUGUSTINE, TX · NPI 1548612807
Verified facts
What the public records show
CMS Open Payments records show David Smith, DNP, FNP-C received $821.26 in general payments during 2025 across 35 reported records.
AstraZeneca Pharmaceuticals LP accounted for 39.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Eliquis, Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Auvelity by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $320.78 | 39.1% | 12 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $156.86 | 19.1% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.52 | 8.1% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.85 | 7.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.83 | 7.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $56.81 | 6.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.78 | 4.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.30 | 3.0% | 1 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $20.00 | 2.4% | 1 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $17.53 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $756.26 | 33 |
| Education | $45.00 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $165.69 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $156.86 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $136.42 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $66.52 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $38.06 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.78 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $31.30 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $30.55 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| PowerGlide Normalized: powerglide |
Device | Becton, Dickinson and Company | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 76 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 230 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 189 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 24 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
230 | 61 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
79 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
189 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 296 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 101 |
| Atorvastatin Calcium | Atorvastatin Calcium | 273 | 95 |
| Prednisone | Prednisone | 242 | 150 |
| Levothyroxine Sodium | Levothyroxine Sodium | 231 | 76 |
| Farxiga | Dapagliflozin Propanediol | 230 | 61 |
| Ozempic | Semaglutide | 189 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 69 |
| Furosemide | Furosemide | 178 | 68 |
| Potassium Chloride | Potassium Chloride | 169 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 51 |
| Losartan Potassium | Losartan Potassium | 150 | 55 |
| Lisinopril | Lisinopril | 147 | 41 |
| Omeprazole | Omeprazole | 141 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 41 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 104 | 24 |
| Trazodone Hcl | Trazodone Hcl | 104 | 34 |
| Famotidine | Famotidine | 103 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 33 |
| Tramadol Hcl | Tramadol Hcl | 96 | 33 |
| Alprazolam | Alprazolam | 95 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 34 |
| Pregabalin | Pregabalin | 94 | 25 |
| Azithromycin | Azithromycin | 85 | 67 |
| Carvedilol | Carvedilol | 82 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 30 |
| Mounjaro | Tirzepatide | 79 | 23 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 78 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 78 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 23 |
| Eliquis | Apixaban | 76 | 24 |
| Methocarbamol | Methocarbamol | 71 | 36 |
| Montelukast Sodium | Montelukast Sodium | 70 | 23 |
| Sertraline Hcl | Sertraline Hcl | 70 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 49 |
| Alendronate Sodium | Alendronate Sodium | 62 | 14 |
| Metformin Hcl Er | Metformin Hcl | 62 | 18 |
| Simvastatin | Simvastatin | 61 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 17 |
| Clonidine Hcl | Clonidine Hcl | 59 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 16 |
| Clonazepam | Clonazepam | 57 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 18 |
| Entresto | Sacubitril/Valsartan | 54 | 13 |
| Allopurinol | Allopurinol | 52 | 14 |
| Celecoxib | Celecoxib | 50 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 17 |
| Ondansetron Odt | Ondansetron | 47 | 30 |
| Fluconazole | Fluconazole | 46 | 24 |
| Xarelto | Rivaroxaban | 45 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 14 |
| Metformin Hcl | Metformin Hcl | 43 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 16 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 37 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 37 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | 18 |
| Meloxicam | Meloxicam | 35 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | 12 |
| Ibuprofen | Ibuprofen | 31 | 13 |
| Levofloxacin | Levofloxacin | 31 | 22 |
| Naproxen | Naproxen | 31 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Spironolactone | Spironolactone | 30 | 12 |
| Buspirone Hcl | Buspirone Hcl | 29 | 12 |
| Chlorthalidone | Chlorthalidone | 29 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 23 |
| Linzess | Linaclotide | 29 | 11 |
| Lovastatin | Lovastatin | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 19 |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 16 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | 11 |
| Estradiol | Estradiol | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $821.26 · 35 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FARXIGA, JARDIANCE, NURTEC ODT, Ozempic, PowerGlide, Rybelsus, Symbravo, TEVIMBRA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error